查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813887

转氨酶检测市场规模、份额和趋势分析报告：按检测类型、技术、最终用途、地区和细分市场预测，2025 年至 2033 年

Transaminase Test Market Size, Share & Trends Analysis Report By Test Type, By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

转氨酶检测市场摘要

预计 2024 年全球转氨酶检测市场价值将达到 41 亿美元，到 2033 年预计将达到 78.1 亿美元，2025 年至 2033 年的复合年增长率为 7.54%。

市场以AST（天门冬胺酸转氨酶）和GOT（麸胺酸转氨酶）等快速且准确的诊断平台为主，广泛用于肝功能评估、疾病监测和一般健康筛检。

随着人们对肝病的认识不断提高，以及这些平台在医院、诊所和照护现场的广泛应用，它们支持及时的临床决策。转氨酶检测产业的成长得益于技术进步和新兴市场日益普及的双重驱动。照护现场AST/GOT 设备的技术创新，加上人工智慧解读的增强，正在缩短週转时间并提高准确性。可携式设备以及软体主导的自动化技术，正在将检测范围从设备齐全的实验室扩展到门诊和乡村地区。

另一个主要成长要素是全球肝病负担的不断加重。非酒精性脂肪肝病 (NAFLD)、病毒性肝炎和酒精性肝病的盛行率不断上升，凸显了定期进行转氨酶筛检的必要性。再加上人口老化和预防性医疗保健计划的实施，推动了对可靠且经济高效的肝臟生物标记检测的需求。

2025年3月，欧洲药品管理局 (EMA) 批准在临床试验中使用人工智慧 (AI) 工具 AIM-NASH，以评估代谢功能障碍核准性脂肪性肝炎 (MASH)（一种严重的脂肪肝疾病）的严重程度。 AIM-NASH 采用机器学习技术开发，使用来自 59 位病理学家的超过 100,000 条註释进行训练，并评估了九项大型临床试验中的 5,000 多例肝臟切片检查。 EMA 人用药物委员会确认，AIM-NASH 能够可靠地从切片检查中确定疾病活动性，且变异性低于目前通常依赖三位病理学家达成共识的标准。这项进展有望为临床试验中新治疗方法的效用提供更明确的证据。

总体而言，受技术进步和医疗保健需求不断增长的推动，全球转氨酶检测市场正在经历重大转型。将人工智慧 (AI) 融入诊断平台，可提高肝功能评估的准确性和效率，从而实现更早的发现和个人化治疗策略。就地检验(POCT) 提供了一种快速且方便的检测方式，扩大了肝臟诊断的可近性，尤其是在偏远和服务不足的地区。此外，非侵入性诊断工具的发展正在减少对传统切片检查程序的依赖，鼓励患者和医疗保健专业人员优先选择微创方法。

由于此类创新改善了患者的治疗效果并重塑了竞争格局，主要企业正在投资研发以保持市场领先地位。随着对高效且易于获取的肝病诊断的需求不断增长，市场已准备好实现持续增长，为公司提供利用新兴技术和满足全球医疗保健生态系统不断变化的需求的机会。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素
    • 肝病盛行率不断上升
    • 诊断技术的进步
    • 扩大预防性医疗保健和筛检项目
  • 市场限制因素分析
    • 低收入地区认知度较低
    • 成本和基础设施障碍
  • 商业环境分析
    • 依因素（政治/法律、经济/技术）进行 SWOT 分析
    • 波特五力分析

第四章 检验类业务分析

  • 转氨酶检测市场：检测类型变化分析
  • ALT检测
  • AST 测试
  • 多项转氨酶检测
  • 其他的

第五章：技术业务分析

  • 转氨酶检测市场：技术变革分析
  • 自动分析仪
  • 半自动和手动系统
  • 照护现场(POC) 设备
  • 纸基/实验室晶片平台
  • 其他的

第六章：应用业务分析

  • 转氨酶检测市场：应用差异分析
  • 肝病的诊断与监测
  • 肝炎筛检
  • 药物性肝损伤（DILI）监测
  • 其他的

第七章 最终用途业务分析

  • 转氨酶检测市场：最终用途变异分析
  • 医院和诊所
  • 诊断实验室（集中检测）
  • 研究机构
  • 家庭检测
  • 其他的

第八章 区域业务分析

  • 2024年及2033年转氨酶检测市占率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 参与企业概况
  • 财务表现
  • 参与企业
    • 市场领导者
    • 转氨酶检测市占率分析，2024年
    • 公司简介
      • F. Hoffmann-La Roche AG
      • Abbott
      • Thermo Fisher Scientific
      • Siemens Healthineers
      • Danaher
      • Randox Laboratories Ltd
      • ELITechGroup
      • Horiba Medical
      • Alpha Laboratories
      • Laboratory Corporation of America Holdings (LabCorp)
      • Bio-Rad Laboratories, Inc.
      • bioMerieux
    • 战略地图
Product Code: GVR-4-68040-710-5

Transaminase Test Market Summary

The global transaminase test market size was estimated at USD 4.10 billion in 2024 and is projected to reach USD 7.81 billion by 2033, growing at a CAGR of 7.54% from 2025 to 2033. This market centers on rapid, accurate diagnostic platforms, such as AST (Aspartate Transaminase) and GOT (Glutamic Oxaloacetic Transaminase) assays, used extensively in liver function assessment, disease monitoring, and general health screening.

These platforms support timely clinical decisions, driven by increasing awareness of liver diseases and widespread integration into hospital, clinical, and point-of-care settings. The growth in the transaminase test industry is propelled by a combination of advancing technology and increasing access in emerging markets. Innovations in point-of-care AST/GOT devices-bolstered by AI-enabled interpretation-are reducing turnaround times and improving precision. Accessibility is expanding beyond well-resourced labs to outpatient clinics and rural settings, thanks to portable formats and software-driven automation.

Another major growth driver is the rising global burden of liver disease. The increasing prevalence of non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and alcohol-related liver conditions underscores the need for regular transaminase screening. Coupled with aging populations and preventive health programs, demand is mounting for reliable, cost-effective liver biomarker tests.

In March 2025, the European Medicines Agency (EMA) approved the use of the artificial intelligence (AI) tool AIM-NASH in clinical trials to assess the severity of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Developed using machine learning, AIM-NASH was trained with over 100,000 annotations from 59 pathologists and evaluated more than 5,000 liver biopsies across nine large clinical trials. The EMA's human medicines committee confirmed that AIM-NASH can reliably determine disease activity from biopsies with less variability than the current standard, which typically relies on a consensus of three pathologists. This advancement is expected to enhance the clarity of evidence regarding the benefits of new treatments in clinical trials.

Overall, the global transaminase test market is experiencing significant transformation, driven by technological advancements and evolving healthcare needs. Integrating artificial intelligence (AI) into diagnostic platforms enhances the precision and efficiency of liver function assessments, enabling earlier detection and personalized treatment strategies. Point-of-care testing (POCT) expands access to liver diagnostics, particularly in remote and underserved regions, by providing rapid and convenient testing options. Furthermore, developing non-invasive diagnostic tools reduces reliance on traditional biopsy procedures, aligning with the growing preference for less invasive methods among patients and healthcare providers.

These innovations are improving patient outcomes and reshaping the competitive landscape, prompting key players to invest in research and development to stay at the forefront of the market. With the demand for efficient and accessible liver diagnostics continuing to rise, the market is well-positioned for sustained growth, offering opportunities for companies to leverage emerging technologies and meet the evolving needs of the global healthcare ecosystem.

Global Transaminase Test Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the transaminase test market on the basis of test type, technology, application, end use, and region:

  • Test Type Outlook (Revenue, USD Million, 2021 - 2033)
  • ALT Test
  • AST Test
  • Combined Transaminase Panels
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Automated Analyzers
  • Semi-Automated & Manual Systems
  • Point-of-Care (POC) Devices
  • Paper-Based / Lab-on-a-Chip Platforms
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Liver Disease Diagnosis & Monitoring
  • Hepatitis Screening
  • Drug-Induced Liver Injury (DILI) Monitoring
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories (centralized testing)
  • Research Institutes
  • Home Testing
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising Prevalence of Liver Diseases
    • 3.4.2. Advancements in Diagnostic Technologies
    • 3.4.3. Expansion of Preventive Healthcare & Screening Programs
  • 3.5. Market Restraint Analysis
    • 3.5.1. Limited Awareness in Low-Income Regions
    • 3.5.2. Cost & Infrastructure Barriers
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Test Type Business Analysis

  • 4.1. Transaminase Test Market: Test Type Movement Analysis
  • 4.2. ALT Test
    • 4.2.1. ALT Test Market, 2021 - 2033 (USD Million)
  • 4.3. AST Test
    • 4.3.1. AST Test Market, 2021 - 2033 (USD Million)
  • 4.4. Combined Transaminase Panels
    • 4.4.1. Combined Transaminase Panels Market, 2021 - 2033 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

  • 5.1. Transaminase Test Market: Technology Movement Analysis
  • 5.2. Automated Analyzers
    • 5.2.1. Automated Analyzers Market, 2021 - 2033 (USD Million)
  • 5.3. Semi-Automated & Manual Systems
    • 5.3.1. Semi-Automated & Manual Systems Market, 2021 - 2033 (USD Million)
  • 5.4. Point-of-Care (POC) Devices
    • 5.4.1. Point-of-Care (POC) Devices Market, 2021 - 2033 (USD Million)
  • 5.5. Paper-Based / Lab-on-a-Chip Platforms
    • 5.5.1. Paper-Based / Lab-on-a-Chip Platforms Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. Transaminase Test Market: Application Movement Analysis
  • 6.2. Liver Disease Diagnosis & Monitoring
    • 6.2.1. Liver Disease Diagnosis & Monitoring Market, 2021 - 2033 (USD Million)
  • 6.3. Hepatitis Screening
    • 6.3.1. Hepatitis Screening Market, 2021 - 2033 (USD Million)
  • 6.4. Drug-Induced Liver Injury (DILI) Monitoring
  • 6.5. Others
    • 6.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Transaminase Test Market: End Use Movement Analysis
  • 7.2. Hospitals & Clinics
    • 7.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • 7.3. Diagnostic Laboratories (centralized testing)
    • 7.3.1. Diagnostic Laboratories (centralized testing) Market, 2021 - 2033 (USD Million)
  • 7.4. Research Institutes
    • 7.4.1. Research Institutes Market, 2021 - 2033 (USD Million)
  • 7.5. Home Testing
    • 7.5.1. Home Testing Market, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Transaminase Test Market Share By Region, 2024 & 2033
  • 8.2. North America
    • 8.2.1. North America Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Transaminase Test market, 2021 - 2033 (USD MILLION)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Mexico Transaminase Test market, 2021 - 2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Transaminase Test market, 2021 - 2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Transaminase Test market, 2021 - 2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Argentina Transaminase Test market, 2021 - 2033 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Transaminase Test market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Transaminase Test Market Share Analysis, 2024
    • 9.3.3. Company Profiles
      • 9.3.3.1. F. Hoffmann-La Roche AG
        • 9.3.3.1.1. Company Overview
        • 9.3.3.1.2. Financial Performance
        • 9.3.3.1.3. Product Benchmarking
        • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Abbott
        • 9.3.3.2.1. Company Overview
        • 9.3.3.2.2. Financial Performance
        • 9.3.3.2.3. Product Benchmarking
        • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. Thermo Fisher Scientific
        • 9.3.3.3.1. Company Overview
        • 9.3.3.3.2. Financial Performance
        • 9.3.3.3.3. Product Benchmarking
        • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. Siemens Healthineers
        • 9.3.3.4.1. Company Overview
        • 9.3.3.4.2. Financial Performance
        • 9.3.3.4.3. Product Benchmarking
        • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. Danaher
        • 9.3.3.5.1. Company Overview
        • 9.3.3.5.2. Financial Performance
        • 9.3.3.5.3. Product Benchmarking
        • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Randox Laboratories Ltd
        • 9.3.3.6.1. Company Overview
        • 9.3.3.6.2. Financial Performance
        • 9.3.3.6.3. Product Benchmarking
        • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. ELITechGroup
        • 9.3.3.7.1. Company Overview
        • 9.3.3.7.2. Financial Performance
        • 9.3.3.7.3. Product Benchmarking
        • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Horiba Medical
        • 9.3.3.8.1. Company Overview
        • 9.3.3.8.2. Financial Performance
        • 9.3.3.8.3. Product Benchmarking
        • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. Alpha Laboratories
        • 9.3.3.9.1. Company Overview
        • 9.3.3.9.2. Financial Performance
        • 9.3.3.9.3. Product Benchmarking
        • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. Laboratory Corporation of America Holdings (LabCorp)
        • 9.3.3.10.1. Company Overview
        • 9.3.3.10.2. Financial Performance
        • 9.3.3.10.3. Product Benchmarking
        • 9.3.3.10.4. Strategic Initiatives
      • 9.3.3.11. Bio-Rad Laboratories, Inc.
        • 9.3.3.11.1. Company Overview
        • 9.3.3.11.2. Financial Performance
        • 9.3.3.11.3. Product Benchmarking
        • 9.3.3.11.4. Strategic Initiatives
      • 9.3.3.12. bioMerieux
        • 9.3.3.12.1. Company Overview
        • 9.3.3.12.2. Financial Performance
        • 9.3.3.12.3. Product Benchmarking
        • 9.3.3.12.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Disease Type/Drug Class Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others

List of Tables

  • TABLE 1 Transaminase Test Market- Industry Snapshot & Key Buying Criteria, 2021 - 2033
  • TABLE 2 Global Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 3 Global Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 4 Global Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 5 Global Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 6 Global Transaminase Test Market, By Region, 2021 - 2033 (USD Million)
  • TABLE 7 Transaminase Test- Key Market Driver Analysis
  • TABLE 8 Transaminase Test- Key Market Restraint Analysis
  • TABLE 9 North America Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 10 North America Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 11 North America Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 12 North America Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 13 North America Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 14 U.S. Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 15 U.S. Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 16 U.S. Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 17 U.S. Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 18 Canada Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 19 Canada Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 20 Canada Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 21 Canada Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 22 Mexico Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 23 Mexico Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 24 Mexico Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 25 Mexico Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 26 Europe Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 27 Europe Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 28 Europe Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 29 Europe Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 30 Europe Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 31 Germany Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 32 Germany Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 33 Germany Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 34 Germany Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 35 Uk Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 36 Uk Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 37 Uk Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 38 Uk Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 39 France Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 40 France Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 41 France Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 42 France Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 43 Italy Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 44 Italy Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 45 Italy Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 46 Italy Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 47 Spain Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 48 Spain Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 49 Spain Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 50 Spain Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 51 Denmark Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 52 Denmark Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 53 Denmark Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 54 Denmark Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 55 Sweden Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 56 Sweden Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 57 Sweden Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 58 Sweden Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 59 Norway Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 60 Norway Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 61 Norway Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 62 Norway Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 63 Asia Pacific Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 64 Asia Pacific Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 65 Asia Pacific Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 66 Asia Pacific Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 67 Asia Pacific Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 68 Japan Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 69 Japan Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 70 Japan Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 71 Japan Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 72 China Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 73 China Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 74 China Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 75 China Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 76 India Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 77 India Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 78 India Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 79 India Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 80 Australia Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 81 Australia Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 82 Australia Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 83 Australia Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 84 South Korea Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 85 South Korea Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 86 South Korea Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 87 South Korea Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 88 Thailand Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 89 Thailand Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 90 Thailand Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 91 Thailand Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 92 Latin America Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 93 Latin America Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 94 Latin America Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 95 Latin America Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 96 Latin America Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 97 Brazil Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 98 Brazil Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 99 Brazil Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 100 Brazil Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 101 Argentina Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 102 Argentina Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 103 Argentina Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 104 Argentina Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 105 MEAMEA Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 106 MEA Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 107 MEA Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 108 MEA Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 109 MEA Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 110 South Africa Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 111 South Africa Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 112 South Africa Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 113 South Africa Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 114 Saudi Arabia Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 115 Saudi Arabia Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 116 Saudi Arabia Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 117 Saudi Arabia Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 118 UAE Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 119 UAE Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 120 UAE Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 121 UAE Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 122 Kuwait Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 123 Kuwait Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 124 Kuwait Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 125 Kuwait Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • FIG. 1 Transaminase Test Market Segmentation
  • FIG. 2 Global Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 3 Transaminase Test Market Dynamics
  • FIG. 4 Transaminase Test Market - Porter's Analysis
  • FIG. 5 Transaminase Test Market - PESTEL Analysis
  • FIG. 6 Transaminase Test Revenue Share, By Test Type, 2024 & 2033
  • FIG. 7 ALT Test Market, 2021 - 2033 (USD Million)
  • FIG. 8 AST Test Market, 2021 - 2033 (USD Million)
  • FIG. 9 Combined Transaminase Panels Market, 2021 - 2033 (USD Million)
  • FIG. 10 Others Market, 2021 - 2033 (USD Million)
  • FIG. 11 Transaminase Test Revenue Share, By Technology, 2024 & 2033
  • FIG. 12 Automated Analyzers Market, 2021 - 2033 (USD Million)
  • FIG. 13 Semi-Automated & Manual Systems Market, 2021 - 2033 (USD Million)
  • FIG. 14 Point-of-Care (POC) Devices Market, 2021 - 2033 (USD Million)
  • FIG. 15 Paper-Based / Lab-on-a-Chip Platforms Market, 2021 - 2033 (USD Million)
  • FIG. 16 Others Market, 2021 - 2033 (USD Million) Market, 2021 - 2033 (USD Million)
  • FIG. 17 Transaminase Test Revenue Share, By Application, 2024 & 2033
  • FIG. 18 Liver Disease Diagnosis & Monitoring Market, 2021 - 2033 (USD Million)
  • FIG. 19 Hepatitis Screening Market, 2021 - 2033 (USD Million)
  • FIG. 20 Drug-Induced Liver Injury (DILI) Monitoring Market, 2021 - 2033 (USD Million)
  • FIG. 21 Others Market, 2021 - 2033 (USD Million) Market, 2021 - 2033 (USD Million)
  • FIG. 22 Transaminase Test Revenue Share, By End Use, 2024 & 2033
  • FIG. 23 Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • FIG. 24 Diagnostic Laboratories (centralized testing) Market, 2021 - 2033 (USD Million)
  • FIG. 25 Research Institutes Market, 2021 - 2033 (USD Million)
  • FIG. 26 Home testing Market, 2021 - 2033 (USD Million)
  • FIG. 27 Others Market, 2021 - 2033 (USD Million)
  • FIG. 28 Transaminase Test Revenue Share, By Region, 2024 & 2033
  • FIG. 29 North America Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 30 U.S. Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 31 Canada Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 32 Mexico Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 33 Europe Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 34 Germany Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 35 UK Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 36 France Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 37 Italy Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 38 Spain Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 39 Denmark Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 40 Sweden Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 41 Norway Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 42 Asia Pacific Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 43 Japan Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 44 China Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 45 India Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 46 Australia Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 47 South Korea Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 48 Thailand Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 49 Latin America Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 50 Brazil Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 51 Argentina Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 52 MEA Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 53 South Africa Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 54 Saudi Arabia Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 55 UAE Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 56 Kuwait Transaminase Test Market, 2021 - 2033 (USD Million)